Gut Microbiome May Influence How Patients With Non-Hodgkin Lymphoma Respond to CAR-T Cell Therapy

Janssen Presents First-ever Results from Dual Bispecific Combination Study Showing 96 Percent Overall Response Rate in Patients With Relapsed or Refractory Multiple Myeloma

Phase 1 Trial of KN046, a Novel Bispecific Antibody Targeting PD-L1 and CTLA-4 in Patients With Advanced Solid Tumors

HD201 Comparable to Referent Trastuzumab for HER2-Positive Breast Cancer

Preclinical Characterization and Phase 1 Trial Results of INBRX-109, a Third-generation, Recombinant, Humanized, Death Receptor 5 Agonist Antibody, in Chondrosarcoma

IMscin001 Part 2: A Randomised Phase 3, Open-label, Multicentre Study Examining the Pharmacokinetics, Efficacy, Immunogenicity, and Safety of Atezolizumab Subcutaneous versus Intravenous in Previously Treated Locally Advanced or Metastatic NSCLC

Menstrual Suppression in the Myelosuppressed: A Retrospective Cohort Study

Camrelizumab Plus Apatinib and Temozolomide as First-line Treatment in Patients With Advanced Acral Melanoma

Gut Microbiome May Influence How Patients With Non-Hodgkin Lymphoma Respond to CAR-T Cell Therapy

header-info

Mar, 20, 2023

Researchers have revealed how microorganisms in the gut may influence the outcomes of patients with non-Hodgkin lymphoma who are also undergoing CAR-T cell therapy. After examining patient outcomes in those who received either no or lower-risk antibiotics, it was discovered that patients who had higher levels of the bacterium Bifidobacterium longum had an improved overall survival rate after CAR-T cell therapy compared with those whose microbiome diversity was reduced and included lower levels of the bacterium.

Access the full article to read more here.